EUS Guided Portal-systemic Pressure Gradient Measurement to Predict Treatment Response and Outcomes of Varices to Endoscopic Variceal Ligation in Patients With Chronic Hepatitis.

Status: Recruiting
Location: See location...
Intervention Type: Device
Study Type: Interventional
Study Phase: Not Applicable
SUMMARY

The aim of the current study is to assess if EUS-PPGM could predict the treatment response and outcomes of varices to endoscopic variceal ligation (EVL) in patients with chronic hepatitis. The hypothesis is that a high EUS-PPGM value at 3 months correlates with the presence of varices requiring EVL in patients that have received primary or secondary variceal prophylaxis on 1 year follow-up upper endoscopy.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Maximum Age: 75
Healthy Volunteers: f
View:

• Age between 18 to 75 years old

• Informed consent available

• Suffering from chronic hepatitis induced cirrhosis

• Suffering from oesophageal varices and received EVL as a result of

‣ Primary variceal prophylaxis during a variceal surveillance program on oesophagogastroduodenoscopy (OGD) or

⁃ Secondary variceal prophylaxis after EVL in patients with active oesophageal variceal bleeding

• Or bleeding gastric varices that have received endoscopic canoacrylate injection

Locations
Other Locations
China
Chinese University of Hong Kong
RECRUITING
Hong Kong
Contact Information
Primary
Anthony Teoh
anthonyteoh@surgery.cuhk.edu.hk
852-35052956
Time Frame
Start Date: 2022-11-01
Estimated Completion Date: 2025-10-31
Participants
Target number of participants: 160
Treatments
Experimental: EUS guided portal pressure gradient measurement
At index OGD, the presence and severity of OV, GV and portal hypertensive gastropathy would be recorded. After endoscopic treatment of varices, recruited patients would undergo 1st measurement of EUS-PPG within 10-14 days after index OGD. The patients would then be enrolled into a variceal surveillance program and be started on B-blockers if not already prescribed. The patients would then be scheduled for another follow-up OGD at 3 months with measurement of the 2nd EUS-PPG. Finally, a third follow-up OGD and EUS-PPG would be performed in 1-year after 1st EUS-PPG. Endoscopic findings attributed to chronic cirrhosis would be assessed in the 3 months and 1 year OGD and the presence and severity of OV, GV and portal hypertensive gastropathy would be recorded.
Related Therapeutic Areas
Sponsors
Leads: Chinese University of Hong Kong

This content was sourced from clinicaltrials.gov